Literature DB >> 24183972

Next-generation NAMPT inhibitors identified by sequential high-throughput phenotypic chemical and functional genomic screens.

Christina J Matheny1, Michael C Wei, Michael C Bassik, Alicia J Donnelly, Martin Kampmann, Masayuki Iwasaki, Obdulio Piloto, David E Solow-Cordero, Donna M Bouley, Rachel Rau, Patrick Brown, Michael T McManus, Jonathan S Weissman, Michael L Cleary.   

Abstract

Phenotypic high-throughput chemical screens allow for discovery of small molecules that modulate complex phenotypes and provide lead compounds for novel therapies; however, identification of the mechanistically relevant targets remains a major experimental challenge. We report the application of sequential unbiased high-throughput chemical and ultracomplex small hairpin RNA (shRNA) screens to identify a distinctive class of inhibitors that target nicotinamide phosphoribosyl transferase (NAMPT), a rate-limiting enzyme in the biosynthesis of nicotinamide adenine dinucleotide, a crucial cofactor in many biochemical processes. The lead compound STF-118804 is a highly specific NAMPT inhibitor, improves survival in an orthotopic xenotransplant model of high-risk acute lymphoblastic leukemia, and targets leukemia stem cells. Tandem high-throughput screening using chemical and ultracomplex shRNA libraries, therefore, provides a rapid chemical genetics approach for seamless progression from small-molecule lead identification to target discovery and validation.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 24183972      PMCID: PMC3881547          DOI: 10.1016/j.chembiol.2013.09.014

Source DB:  PubMed          Journal:  Chem Biol        ISSN: 1074-5521


  44 in total

Review 1.  The Connectivity Map: a new tool for biomedical research.

Authors:  Justin Lamb
Journal:  Nat Rev Cancer       Date:  2007-01       Impact factor: 60.716

2.  Long-term growth of malignant thymocytes in vitro.

Authors:  S D Smith; P McFall; R Morgan; M Link; F Hecht; M Cleary; J Sklar
Journal:  Blood       Date:  1989-06       Impact factor: 22.113

3.  Display and analysis of patterns of differential activity of drugs against human tumor cell lines: development of mean graph and COMPARE algorithm.

Authors:  K D Paull; R H Shoemaker; L Hodes; A Monks; D A Scudiero; L Rubinstein; J Plowman; M R Boyd
Journal:  J Natl Cancer Inst       Date:  1989-07-19       Impact factor: 13.506

4.  WK175, a novel antitumor agent, decreases the intracellular nicotinamide adenine dinucleotide concentration and induces the apoptotic cascade in human leukemia cells.

Authors:  Katja Wosikowski; Karin Mattern; Isabel Schemainda; Max Hasmann; Benno Rattel; Roland Löser
Journal:  Cancer Res       Date:  2002-02-15       Impact factor: 12.701

5.  An information-intensive approach to the molecular pharmacology of cancer.

Authors:  J N Weinstein; T G Myers; P M O'Connor; S H Friend; A J Fornace; K W Kohn; T Fojo; S E Bates; L V Rubinstein; N L Anderson; J K Buolamwini; W W van Osdol; A P Monks; D A Scudiero; E A Sausville; D W Zaharevitz; B Bunow; V N Viswanadhan; G S Johnson; R E Wittes; K D Paull
Journal:  Science       Date:  1997-01-17       Impact factor: 47.728

6.  hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase.

Authors:  H Vaziri; S K Dessain; E Ng Eaton; S I Imai; R A Frye; T K Pandita; L Guarente; R A Weinberg
Journal:  Cell       Date:  2001-10-19       Impact factor: 41.582

7.  Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase.

Authors:  S Imai; C M Armstrong; M Kaeberlein; L Guarente
Journal:  Nature       Date:  2000-02-17       Impact factor: 49.962

8.  A Phase I study of CHS 828 in patients with solid tumor malignancy.

Authors:  Peter Hovstadius; Rolf Larsson; Elin Jonsson; Torsten Skov; Anne-Marie Kissmeyer; Klaus Krasilnikoff; Jonas Bergh; Mats O Karlsson; Anna Lönnebo; Johan Ahlgren
Journal:  Clin Cancer Res       Date:  2002-09       Impact factor: 12.531

9.  Cell cycle effects of CB30865, a lipophilic quinazoline-based analogue of the antifolate thymidylate synthase inhibitor ICI 198583 with an undefined mechanism of action.

Authors:  L A Skelton; M G Ormerod; J C Titley; A L Jackman
Journal:  Cytometry       Date:  1998-09-01

10.  FK866, a highly specific noncompetitive inhibitor of nicotinamide phosphoribosyltransferase, represents a novel mechanism for induction of tumor cell apoptosis.

Authors:  Max Hasmann; Isabel Schemainda
Journal:  Cancer Res       Date:  2003-11-01       Impact factor: 12.701

View more
  44 in total

Review 1.  Functional genomics to uncover drug mechanism of action.

Authors:  Sebastian M B Nijman
Journal:  Nat Chem Biol       Date:  2015-11-17       Impact factor: 15.040

2.  LMO2 activation by deacetylation is indispensable for hematopoiesis and T-ALL leukemogenesis.

Authors:  Tatsuya Morishima; Ann-Christin Krahl; Masoud Nasri; Yun Xu; Narges Aghaallaei; Betül Findik; Maksim Klimiankou; Malte Ritter; Marcus D Hartmann; Christian Johannes Gloeckner; Sylwia Stefanczyk; Christian Lindner; Benedikt Oswald; Regine Bernhard; Karin Hähnel; Ursula Hermanutz-Klein; Martin Ebinger; Rupert Handgretinger; Nicolas Casadei; Karl Welte; Maya Andre; Patrick Müller; Baubak Bajoghli; Julia Skokowa
Journal:  Blood       Date:  2019-07-31       Impact factor: 22.113

3.  CBP Modulates Sensitivity to Dasatinib in Pre-BCR+ Acute Lymphoblastic Leukemia.

Authors:  Jesús Duque-Afonso; Chiou-Hong Lin; Kyuho Han; David W Morgens; Edwin E Jeng; Ziming Weng; Johan Jeong; Stephen Hon Kit Wong; Li Zhu; Michael C Wei; Hee-Don Chae; Martin Schrappe; Gunnar Cario; Justus Duyster; Xiangshu Xiao; Kathleen M Sakamoto; Michael C Bassik; Michael L Cleary
Journal:  Cancer Res       Date:  2018-09-27       Impact factor: 12.701

4.  The mTOR Complex Controls HIV Latency.

Authors:  Emilie Besnard; Shweta Hakre; Martin Kampmann; Hyung W Lim; Nina N Hosmane; Alyssa Martin; Michael C Bassik; Erik Verschueren; Emilie Battivelli; Jonathan Chan; J Peter Svensson; Andrea Gramatica; Ryan J Conrad; Melanie Ott; Warner C Greene; Nevan J Krogan; Robert F Siliciano; Jonathan S Weissman; Eric Verdin
Journal:  Cell Host Microbe       Date:  2016-12-14       Impact factor: 21.023

Review 5.  Elucidating drug targets and mechanisms of action by genetic screens in mammalian cells.

Authors:  Martin Kampmann
Journal:  Chem Commun (Camb)       Date:  2017-06-29       Impact factor: 6.222

6.  A genome-wide analysis of targets of macrolide antibiotics in mammalian cells.

Authors:  Amita Gupta; Aye Ökesli-Armlovich; David Morgens; Michael C Bassik; Chaitan Khosla
Journal:  J Biol Chem       Date:  2020-01-08       Impact factor: 5.157

7.  E2A-PBX1 Remodels Oncogenic Signaling Networks in B-cell Precursor Acute Lymphoid Leukemia.

Authors:  Jesús Duque-Afonso; Chiou-Hong Lin; Kyuho Han; Michael C Wei; Jue Feng; Jason H Kurzer; Corina Schneidawind; Stephen Hon-Kit Wong; Michael C Bassik; Michael L Cleary
Journal:  Cancer Res       Date:  2016-10-07       Impact factor: 12.701

8.  Targeting the vulnerability to NAD+ depletion in B-cell acute lymphoblastic leukemia.

Authors:  S Takao; W Chien; V Madan; D-C Lin; L-W Ding; Q-Y Sun; A Mayakonda; M Sudo; L Xu; Y Chen; Y-Y Jiang; S Gery; M Lill; E Park; W Senapedis; E Baloglu; M Müschen; H P Koeffler
Journal:  Leukemia       Date:  2017-09-14       Impact factor: 11.528

9.  Crystal structure-based comparison of two NAMPT inhibitors.

Authors:  Sai-Long Zhang; Tian-Ying Xu; Zhen-Lin Yang; Shuo Han; Qiang Zhao; Chao-Yu Miao
Journal:  Acta Pharmacol Sin       Date:  2017-08-31       Impact factor: 6.150

10.  NAD as a genotype-specific drug target.

Authors:  Szu-Chieh Mei; Charles Brenner
Journal:  Chem Biol       Date:  2013-11-21
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.